Aix (France), 30 may 2017 Inventiva (Euronext Paris FR0013233012 IVA), a biopharmaceutical company specializing in the development of innovative treatments, including fibrosis, today announced the appointment of Dr. Nanna Lüneborg to its Board of directors, succeeding Mr. Philippe Goupit. Following this appointment, the Board of directors of Inventiva is composed of eight directors (three women and five men) and four independent directors.
Download the free guide
Boost your gains
“On behalf of the Board of directors and of the Society as a whole, we would like to warmly thank Philippe Goupit for his contribution to the development of Inventiva and wish him all our best wishes in her future endeavors,” said Frederic Cren, President and ceo of Inventiva. “To succeed him, we are very pleased to welcome Nanna Lüneborg to our Board of Directors. His experience will be invaluable at this important stage of our development, since we expect that in 2018 the results of three clinical studies. We look forward to be able to benefit from his advice and his valuable contribution. ”
“I am very pleased to join the Board of directors of Inventiva. Inventiva has a portfolio of promising advanced products in areas which arouse a considerable interest in the pharmacy industry. Positive results in the NASH, scleroderma, systemic, or MPS VI would be as many major advances for millions of patients still waiting for an effective treatment, ” added Nanna Lüneborg. “This is an exciting time for the Company. After the success of the ipo, which gives him the financial means of its ambitions, I look forward to working closely with the Board of directors and the executive management team at Inventiva to the next key stages of its development.
About Inventiva : www.inventivapharma.com
Inventiva is a biopharmaceutical company specializing in the development of drugs acting on nuclear receptors, transcription factors and epigenetic modulation. Inventiva opens new avenues for innovative therapies in the field of fibrotic diseases, oncology, and orphan diseases for which the medical need is important.
Its flagship product, IVA337, is a drug candidate that has a unique mechanism of action through activation of the PPAR (receptor activated peroxisome proliferator -) alpha, gamma and delta, which play a fundamental role in the control of the fibrotic process. Its anti-fibrotic in particular allows you to target two indications to strong medical need : the NASH, a severe pathology of the liver in strong growth and which already affects the United States more than 30 million people, and the systemic scleroderma, a disease in which the mortality rate is very high and without any treatment approved to date.
Inventiva is developing in parallel a second clinical program with IVA336, a drug candidate for the treatment of three forms of mucopolysaccharidoses (MPS I, or syndrome, Hurler-Scheie, MPS II, or syndrome, Hunter and MPS VI or Maroteaux-Lamy syndrome), as well as a portfolio of pre-clinical projects in the field of oncology.
Inventiva is surrounded by well-known partners in the area of the research, such as the Curie Institute. Two strategic partnerships, one of which at the clinical stage, have also been put in place with AbbVie and Boehringer Ingelheim, which include, in particular, for the payment to Inventiva of payments based on the achievement of objectives pre-clinical, clinical, regulatory and commercial, as well as royalties on sales of products developed in the framework of these partnerships.
Inventiva employs more than 100 highly qualified people and has R&D facilities of cutting edge purchased at the international pharmaceutical company Abbott, regrouping, near Dijon, a chemical library of more than 240 000 molecules and platforms in biology, chemistry, ADME, and pharmacology.
Download the free guide
Boost your gains
